Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 08, 2015 2:26 PM ET


Company Overview of Altheos, Inc.

Company Overview

Altheos, Inc. identifies and develops small molecule drugs for the treatment of glaucoma and ocular hypertension. The company develops ATS907 and ATS8535, a selective Rho kinase inhibitor for treatment of elevated intraocular pressure associated with glaucoma. The company was founded in 2009 and is based in South San Francisco, California.

601 Gateway Boulevard

Suite 250

South San Francisco, CA 94080

United States

Founded in 2009





Key Executives for Altheos, Inc.

Chief Executive Officer, Co-Founder, and Director
Age: 56
Director of Corporate Administration
Member of Management Board and Director
Age: 41
Compensation as of Fiscal Year 2015.

Similar Private Companies By Industry

Company Name Region
OroGen Bio Sciences, Inc. United States
ChemGenes Corporation United States
Everon Biosciences, Inc. United States
Inhibrx LLC United States
Stowers Institute For Medical Research Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Altheos, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at